All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
How can MRD testing be put to best use in AML?
Featured
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Ali Bazarbachi, American University of Beirut, Beirut, LB. We asked, How can MRD testing be put to best use in AML?
How can MRD testing be put to best use in AML?
In this video, Bazarbachi explains the role of measurable residual disease (MRD) monitoring. The persistence of MRD is a strong predictor for relapse following therapy in AML.
More about...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox